Treatment regimens for tuberculosis in children and related adverse effects

1 Physician, Master’s Candidate in the Graduate Program in Child and Adolescent Health of the Sector of Health Sciences of the Federal University of Paraná (UFPR), Curitiba, Brazil. 2 Physician of the Service of Pediatric Infectology of the Clinics Hospital Complex of the Federal University of Paraná (CHC-UFPR), Curitiba, Brazil. 3 Professor of the Department of Medicine State University of Ponta Grossa, Brazil. 4 Professor of Department of Pediatrics of the Federal University of Paraná (UFPR), Curitiba, Brazil. 5 Professor of the Department of Clinical Medicine of the Federal University of Paraná (UFPR), Curitiba, Brazil.

[1]  C. Sismanidis,et al.  Global burden of drug-resistant tuberculosis in children: a mathematical modelling study. , 2016, The Lancet. Infectious diseases.

[2]  P. Dodd,et al.  Burden of childhood tuberculosis in 22 high-burden countries: a mathematical modelling study. , 2014, The Lancet. Global health.

[3]  Marcello Pagano,et al.  Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates , 2014, The Lancet.

[4]  R. Triasih,et al.  Editorial commentary: more evidence to support screening of child contacts of tuberculosis cases: if not now, then when? , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  P. Godfrey-Faussett,et al.  High treatment success in children treated for multidrug-resistant tuberculosis: an observational cohort study , 2013, Thorax.

[6]  Sonya S. Shin,et al.  Risk Factors for In-Hospital Mortality Among Children With Tuberculosis: The 25-Year Experience in Peru , 2012, Pediatrics.

[7]  N. Ford,et al.  Treatment outcomes for children with multidrug-resistant tuberculosis: a systematic review and meta-analysis. , 2012, The Lancet. Infectious diseases.

[8]  G. Hussey,et al.  Isoniazid plasma concentrations in a cohort of South African children with tuberculosis: implications for international pediatric dosing guidelines. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  M. Lobato,et al.  Unintended Consequences: Mandatory Tuberculin Skin Testing and Severe Isoniazid Hepatotoxicity , 2008, Pediatrics.

[10]  B. Eley,et al.  Culture-confirmed childhood tuberculosis in Cape Town, South Africa: a review of 596 cases , 2007, BMC infectious diseases.

[11]  D. Maher,et al.  Ethambutol dosage for the treatment of children: literature review and recommendations. , 2006, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[12]  P. V. van Helden,et al.  Isoniazid pharmacokinetics in children treated for respiratory tuberculosis , 2005, Archives of Disease in Childhood.

[13]  R. Gie,et al.  The natural history of childhood intra-thoracic tuberculosis: a critical review of literature from the pre-chemotherapy era. , 2004, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[14]  W. Burman,et al.  Treatment of HIV-related tuberculosis in the era of effective antiretroviral therapy. , 2001, American journal of respiratory and critical care medicine.

[15]  U. Wahn,et al.  [Compliance and tolerance of new antitubercular short-term chemopreventive regimens in childhood--a pilot project]. , 1994, Pneumologie.

[16]  J. Blumer,et al.  Clinical pharmacology of antitubercular drugs. , 1983, Pediatric clinics of North America.

[17]  S. Swaminathan,et al.  Towards early inclusion of children in tuberculosis drugs trials: a consensus statement , 2015 .

[18]  A. Kritski,et al.  Epidemiological aspects of tuberculosis in children and adolescents in Rio de Janeiro. , 2012, Jornal de pediatria.

[19]  Ei Ferrol.  Is the combination of pyrazinamide plus rifampicin safe for treating latent tuberculosis infection in persons not infected by the human immunodeficiency virus , 2005 .

[20]  L. Tanoue.  Update: Adverse Event Data and Revised American Thoracic Society/CDC Recommendations Against the Use of Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis Infection—United States, 2003 , 2006 .